FastWave Medical has announced the close of a US$19 million funding round earlier this year, increasing the total capital invested into the company to over US$40 million.
This investment round was led by Epic Venture Partners with participation from M&L Healthcare Investments and the company’s existing investors, and looks to develop FastWave’s ongoing regulatory and clinical initiatives of its portfolio of intravascular lithotripsy (IVL) platforms.
FastWave Medical co-founder and chief executive officer Scott Nelson expressed the team’s excitement: “We are beyond thrilled to partner with physician-led investors like Epic and M&L who see the clinical promise and commercial viability of both our IVL systems. This round of stage-appropriate funding is a testament to the confidence the market has in our approach and takes us one step closer to our goal of empowering interventionalists across the world with next-level IVL therapies.”
Since its formation in 2021, FastWave has been moving in its efforts to tackle the challenges of artery calcification with IVL solutions. As the global population ages, the demand for effective, minimally invasive treatments is escalating. In a recent press release, FastWave have stated that its commitment to providing physicians with highly deliverable IVL catheters that offer durable, 360-degree sonic output has led to the rapid development of a pipeline of IVL systems that hold the potential to positively impact patient care.
“On every metric, FastWave’s pace of innovation stands out,” said Bryan Edelstein, managing partner of Epic Venture Partners. “We are excited to be a part of helping FastWave build on their impressive cadence to reach the company’s next key clinical and regulatory initiatives.”
Arthur Lee, managing partner of Epic Venture Partners, added: “FastWave is moving quickly and decisively to become best-in-class in the IVL space. We are excited to support the FastWave team, as they continue to take down milestone after milestone in their mission to save lives and offer this groundbreaking technology to all who need it.”
Steven Kum, chief medical officer of M&L Healthcare Investments, holds similar optimism: “FastWave Medical has all the hallmarks of a company poised for significant growth and impact. Their commitment to evidence-based development aligns perfectly with our investment philosophy, and we’re excited to be a part of a new era of IVL innovation that addresses the gaps left by current technologies.”
